Related Experiment Video
Updated: Jul 2, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin delivery with FlexPen: dose accuracy, patient preference and adherence
A Pfützner1, T Asakura, B Sommavilla
1Institute for Clinical Research and Development, Mainz, Germany.
Expert Opinion on Drug Delivery
|August 21, 2008
Summary
Insulin pens like FlexPen improve diabetes management by enhancing dosing accuracy and patient ease compared to traditional vials and syringes. Next-generation designs further refine usability and safety for better adherence.
Area of Science:
- Endocrinology
- Pharmaceutical Technology
- Patient Care
Background:
- Insulin pens offer advantages over vial and syringe methods for diabetes management.
- Challenges with traditional methods include dosing inaccuracies, injection fear, and social stigma.
Purpose of the Study:
- To review the evidence on the accuracy, patient preference, and economic impact of the FlexPen insulin delivery device.
- To discuss design advancements in the Next Generation FlexPen.
Main Methods:
- Systematic review of primary research publications evaluating FlexPen.
- Comparative analysis of FlexPen's performance against vial/syringe and other insulin pens (SoloStar, OptiClik).
Main Results:
- FlexPen demonstrated significantly higher accuracy in delivering high, medium, and low insulin doses compared to vial/syringe, SoloStar, and OptiClik.
- Patients reported greater ease of use with FlexPen than with vial and syringe.
- The Next Generation FlexPen maintains accuracy while reducing injection force and improving insulin type identification.
Conclusions:
- FlexPen is a highly accurate and preferred insulin delivery device for patients with Type 1 or Type 2 diabetes.
- Innovations in the Next Generation FlexPen enhance user comfort, safety, and medication error prevention.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...